| Literature DB >> 31889082 |
Miho Murashima1,2, Masatoshi Nishimoto3, Maiko Kokubu4, Takayuki Hamano5,6, Masaru Matsui4, Masahiro Eriguchi3, Ken-Ichi Samejima3, Yasuhiro Akai3, Kazuhiko Tsuruya3.
Abstract
This retrospective cohort study examined the roles of inflammation in acute kidney injury (AKI). Serum albumin and C-reactive protein (CRP) were used as markers of inflammation. Adults who underwent non-cardiac surgery from 2007 to 2011 were included. Exclusion criteria were urological surgery, obstetric surgery, missing data, and pre-operative dialysis. Subjects were followed until the end of 2015 or loss to follow-up. Associations between pre-operative albumin or CRP and post-operative AKI or association between AKI and mortality were examined by logistic or Cox regression, respectively. Mediation analyses were performed using albumin and CRP as mediators. Among 4,538 subjects, 272 developed AKI. Pre-operative albumin was independently associated with AKI (odds ratio [95% confidence interval (CI)]: 0.63 [0.48-0.83]). During a median follow-up of 4.5 years, 649 died. AKI was significantly associated with mortality (hazard ratio [HR] [95% CI]: 1.58 [1.22-2.04]). Further adjustment for pre-operative albumin and CRP attenuated the association (HR [95% CI]: 1.28 [0.99-1.67]). The proportions explained by mediating effects of lnCRP and albumin were 29.3% and 39.2% and mediation effects were statistically significant. In conclusion, inflammation is a predictor of AKI and a mediator of mortality after AKI. Interventions targeting inflammation might improve outcomes of AKI.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31889082 PMCID: PMC6937243 DOI: 10.1038/s41598-019-56615-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow of patients.
Demographics.
| No AKI (n = 4266) | AKI (n = 272) | p | |
|---|---|---|---|
| Age | 63 (50–72) | 67 (55–74) | <0.001 |
| Sex (male) | 1995 (46.8) | 159 (58.5) | <0.001 |
| Body mass index (kg/m2) | 22.3 (22.3–24.8) | 23.4 (21.0–25.8) | <0.001 |
| Diabetes mellitus | 655 (15.4) | 72 (26.5) | <0.001 |
| Hypertension | 1497 (35.1) | 130 (47.8) | <0.001 |
| Atrial fibrillation | 108 (2.5) | 11 (4.0) | 0.17 |
| Congestive heart failure | 54 (1.3) | 14 (5.1) | <0.001 |
| Peripheral vascular disease | 46 (1.1) | 4 (1.5) | 0.54 |
| Ischemic stroke | 235 (5.5) | 13 (4.8) | 0.78 |
| Hemorrhagic stroke | 97 (2.3) | 10 (3.7) | 0.15 |
| Coronary artery disease | 200 (4.7) | 22 (8.1) | 0.02 |
| COPD | 111 (2.6) | 7 (2.6) | 1.00 |
| Chronic hepatitis | 167 (3.9) | 32 (11.8) | <0.001 |
| Liver cirrhosis | 41 (1.0) | 11 (4.0) | <0.001 |
| Malignancy | 1713 (40.2) | 151 (55.5) | <0.001 |
Smoking No Previous Current | 2336 (54.8) 930 (21.8) 1000 (23.4) | 135 (49.6) 80 (29.4) 57 (21.0) | 0.01 |
| CRP (mg/dL) | 0.10 (0.10–0.30) | 0.20 (0.10–1.20) | <0.001 |
| Albumin (g/dL) | 4.3 (4.0–4.5) | 4.0 (3.5–4.3) | <0.001 |
| Hematocrit (%) | 38.2 (34.8–41.5) | 35.5 (31.3–39.5) | <0.001 |
| eGFR (mL/min/1.73m2) | 78.1 (65.9–92.0) | 69.5 (48.5–88.3) | <0.001 |
Dipstick proteinuria − +/− + 2+ 3+ | 3601 (84.4) 310 (7.3) 231 (5.4) 106 (2.5) 18 (0.4) | 182 (66.9) 24 (8.8) 26 (9.6) 29 (10.7) 11 (4.0) | <0.001 |
| ACE-Is or ARBs | 803 (18.8) | 86 (31.6) | <0.001 |
| Diuretics | 276 (6.5) | 44 (16.2) | <0.001 |
| Anti-platelet agents | 546 (12.8) | 46 (16.9) | 0.06 |
| Statins | 481 (11.3) | 41 (15.1) | 0.06 |
| Insulin | 147 (3.4) | 25 (9.2) | <0.001 |
| Oral antidiabetics | 383 (9.0) | 44 (16.2) | <0.001 |
| NSAIDs | 700 (16.4) | 33 (12.1) | 0.07 |
| Contrast media | 231 (5.4) | 21 (7.7) | 0.13 |
| Pre-operative chemotherapy | 218 (5.1) | 13 (4.8) | 1.00 |
| Post-operative chemotherapy | 574 (13.5) | 45 (16.5) | 0.17 |
| Corticosteroids | 229 (5.4) | 21 (7.7) | 0.01 |
Kinds of Surgery Intra-thoracic Intra-abdominal Pelvic or major joint replacement Others | 430 (10.1) 800 (18.8) 662 (15.5) 2374 (55.6) | 35 (12.9) 89 (32.7) 58 (21.3) 90 (33.1) | <0.001 |
Surgeries not for malignancy Curative resection for malignancy Palliative resection for malignancy | 2791 (65.4) 1234 (29.0) 241 (5.6) | 136 (50.0) 110 (40.4) 26 (9.6) | <0.001 |
| Emergent surgery | 210 (4.9) | 24 (8.8) | 0.01 |
| Intra-operative vasopressors | 3482 (81.6) | 236 (86.8) | 0.03 |
| Intra-operative diuretics | 391 (9.2) | 42 (15.4) | 0.001 |
| Intra-operative lowest systolic blood pressure (mmHg) | 80 (70–85) | 75 (70–80) | <0.001 |
| Intra-operative delta systolic blood pressure (mmHg) | 60 (45–80) | 65 (50–80) | 0.04 |
| Intra-operative fluid balance (mL/kg) | 21.2 (14.0–31.4) | 25.6 (16.8–41.3) | <0.001 |
The data were shown as n (%) or median (interquartile range). P values were by Man-Whitney U test or Fisher’s exact test.
Delta systolic blood pressure = systolic blood pressure at the beginning of surgery – intra-operative lowest systolic blood pressure
COPD: chronic obstructive pulmonary disease, CRP: C-reactive protein, eGFR: estimated glomerular filtration rate, ACE-Is: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, NSAIDs: non-steroidal anti-inflammatory drugs.
Predictors of post–operative acute kidney injury.
| OR (95% CI) | |
|---|---|
| Male sex | 1.80 (1.35–2.41) |
| Body mass index (per kg/m2) | 1.10 (1.07–1.14) |
| Congestive heart failure | 2.10 (1.06–4.15) |
| Chronic hepatitis | 2.29 (1.48–3.56) |
| Hematocrit (per 1%) | 0.95 (0.92–0.98) |
| Dipstick proteinuria | |
| (−) | 1 (reference) |
| (+/−) | 1.13 (0.71–1.80) |
| (+) | 1.40 (0.88–2.23) |
| (2+) | 3.11 (1.92–5.02) |
| (3+) | 5.49 (2.29–13.14) |
| Serum albumin (per g/dL) | 0.63 (0.48–0.83) |
| ACE-Is/ARBs | 1.33 (0.99–1.79) |
| Insulin | 1.57 (0.97–2.54) |
| NSAIDs | 0.62 (0.41–0.92) |
| Corticosteroids | 1.51 (0.93–2.44) |
| Pre-operative chemotherapy | 0.64 (0.34-1.20) |
| Intra-thoracic surgery | 1.65 (1.04–2.62) |
| Intra-abdominal surgery | 1.28 (0.87–1.89) |
| Pelvic or major joint surgery | 2.14 (1.45–3.16) |
| Others | 1 (reference) |
| Surgery for malignancy | 1.62 (1.18–2.22) |
| Intra-operative diuretics | 1.54 (1.02–2.31) |
| Intra-operative fluid balance (per mL/kg) | 1.01 (1.00–1.02) |
Predictors of acute kidney injury were selected by backward elimination in logistic regression models from the following variables; age, sex, body mass index, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, atrial fibrillation, congestive heart failure, peripheral arterial disease, ischemic stroke, hemorrhagic stroke, coronary artery disease, history of malignancy, chronic hepatitis, liver cirrhosis, smoking status (never, previous, current), estimated glomerular filtration rate, proteinuria, hematocrit, C-reactive protein (natural log-transformed), serum albumin, pre–operative use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers, diuretics, insulin, oral antidiabetics, antiplatelets, statins, chemotherapy, non-steroidal anti–inflammatory drugs, contrast media, corticosteroids, kinds of surgery (intra-thoracic, intra-abdominal, pelvic or major joint, and others), whether index surgery was for malignancy, emergent surgery, intra–operative use of vasopressors and diuretics, intra-operative lowest systolic blood pressure, intra-operative drop in systolic blood pressure (systolic blood pressure at the beginning of surgery – intra-operative lowest systolic blood pressure), and intra–operative fluid balance. The best fitted model with highest p values (p = 0.87) by Hosmer-Lemeshow test was shown. ACE-Is: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, NSAIDs: non-steroidal anti-inflammatory drugs.
Figure 2Kaplan-Meier curve for all-cause mortality among those with and without AKI. AKI: acute kidney injury.
Figure 3Kaplan-Meier curves for all-cause mortality stratified by AKI status and serum albumin or CRP levels. “High” represents higher than median and “low” represents lower than or equal to median. (A) The light blue, red, green, and orange lines represent survival curves for those without AKI and low albumin, those without AKI and high albumin, those with AKI and low albumin, and those with AKI and high albumin, respectively. (B) The light blue, red, green, and orange lines represent survival curves for those without AKI and low CRP, those without AKI and high CRP, those with AKI and low CRP, and those with AKI and high CRP, respectively. AKI; acute kidney injury, CRP: C-reactive proteins.
Association between acute kidney injury and mortality.
| HR (95% CI) | |
|---|---|
| Model 1 | 1.58 (1.22–2.04) |
| Model 1 + lnCRP | 1.40 (1.08–1.81) |
| Model 1 + lnCRP + serum albumin | 1.28 (0.99–1.67) |
Data were adjusted for age, sex, smoking status (never, previous, current), body mass index, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, atrial fibrillation, congestive heart failure, peripheral arterial disease, ischemic stroke, hemorrhagic stroke, coronary artery disease, history of malignancy, whether index surgery was for malignancy (not for malignancy, curative resection, palliative resection), chronic hepatitis, liver cirrhosis, estimated glomerular filtration rate, proteinuria, the use of angiotensin converting enzyme inhibitors or angiotensin receptor blocker, diuretics, insulin, oral antidiabetics, anti-platelet agents, statin, corticosteroids, pre-operative chemotherapy, or post-operative chemotherapy. CRP: C-reactive protein.
Figure 4Box plots of serum CRP and albumin levels among those with and without AKI. A box represents interquartile range and a horizontal line in the box shows the median value. A bar shows range and outliers are shown in circles. P values were by Man-Whitney U test comparing values for those with and without AKI at each time point. The number of patients with available values was shown in tables below the graphs. CRP: C-reactive protein, AKI: acute kidney injury.